Atrial Fibrillation

Meet the patient

A 72-year-old man arrives at 3am with palpitations and breathlessness that woke him. His radial pulse is a chaotic 140 and will not count; his apex rate is higher still. He is clammy, his systolic BP is 96, and the monitor shows an irregularly irregular broad-complex tachycardia.^[1]

Three exam questions are now live, and this page exists to answer them: is this AF? (the ECG), is he stable? (the fork), and does he need a DOAC? (CHA2DS2-VASc). The one question that can kill him first — is this pre-excited? — is the trap the whole differential turns on.^[2]

The three ECG words — "irregularly irregular, no P, f-waves"

AF is a supraventricular tachyarrhythmia of uncoordinated atrial activation that abolishes effective atrial contraction. Instead of one organised sinus impulse crossing both atria each cycle, a storm of chaotic depolarisations makes the atria quiver; the AV node conducts an irregular subset, and the ventricles fire unpredictably.^[1]

The diagnosis rests on three ECG hallmarks you must recite in one breath:^[1]

1. Irregularly irregular ventricular (RR) rhythm — no pattern to the spacing.
2. Absent P waves — no discrete atrial depolarisation visible.
3. Fibrillatory f-waves — fine, rapid baseline undulations (best in V1) replacing organised atrial activity, at 350 to 600 per minute.^[1]

When f-waves are coarse the rhythm can masquerade as flutter — but flutter gives a regular (or regularly irregular) ventricular response; AF is absolutely irregular. That single word — irregularity — is the discriminator.^[1]

The old label "lone AF" is dead and should stay dead: with modern imaging and risk-factor work, almost everyone has a driver — hypertension, sleep-disordered breathing, or subclinical cardiomyopathy. "No cause found" usually means "no cause yet looked for".^[1]

Classification by time, not by rate — "7 days, 12 months, accepted"

AF is classified by its temporal pattern, never by ventricular rate or symptom burden. The thresholds are examiner favourites because they decide who is offered rhythm control.^[1]

^[1]

Enlarge

Valvular or not — the one classification that changes the drug

How common, how deadly

^[1]

AF is the commonest sustained arrhythmia and still climbing in absolute numbers, dragged up by ageing, obesity, hypertension, and diabetes. Hypertension is the single commonest driver, present in over 70%.^[1]

^[1]

Beyond HIPAT-H, remember obesity (dose-response with incidence and recurrence after ablation), diabetes, rheumatic and valvular disease (the dominant cause across the Indian subcontinent), post-cardiac-surgery state (30–40% of bypass and valve patients), pericarditis and myocarditis, endurance-athlete remodelling, and family history (doubles risk).^[1]

Why AF is dangerous is rarely the rhythm itself — it is the complications. Four cardinal ones: a large, severe cardioembolic stroke; heart failure (cause and consequence, and a potentially reversible tachycardiomyopathy); cognitive decline from silent micro-infarcts; and roughly doubled all-cause mortality.^[1]

Why the atria fibrillate — "triggers in the veins, wavelets in the walls"

Two overlapping mechanisms sustain AF, and together they make the rationale for ablation obvious.^[1]

1. Focal triggers — most often rapidly firing ectopic foci in the muscular sleeves of myocardium extending 1–3 cm into the pulmonary veins. These sleeves have intrinsic automaticity and fire the bursts that initiate AF, especially the paroxysmal kind. Electrically isolating the veins (PVI) removes the trigger — the cornerstone of ablation.^[1]
2. Multiple re-entrant wavelets — once started, AF is maintained by chaotic wavelets circling through atrial tissue made re-entry-friendly by heterogeneous conduction and shortened, dispersed refractory periods (atrial dilation, fibrosis, the myopathy of long-standing AF). This is Moe and Allessie's wavelet hypothesis.^[1]

Enlarge

"AF begets AF" — the remodelling sentence

Electrical and structural remodelling is why AF gets harder to terminate the longer it runs. Within days, atrial myocytes down-regulate the L-type calcium current and up-regulate the inward-rectifier potassium current — shortening the action potential and refractory period, exactly the change that favours more re-entry. Over months come fibrosis, fatty infiltration, and dilation.^[1]

That biological fact is the whole argument for early rhythm control (EAST-AFNET 4) and aggressive risk-factor modification — weight, blood pressure, sleep apnoea — before remodelling sets in.^[3][1]

The irregularly irregular ventricular response

The AV node is bombarded by 350–600 atrial depolarisations a minute but conducts only a variable, unpredictable subset — governed by concealed conduction and refractoriness inside the node. The result is the diagnostic irregular irregularity of the RR intervals.^[1]

The untreated ventricular rate is usually 100–160 bpm, faster in sympathetic states (sepsis, thyrotoxicosis, post-op) and deceptively slow when the node is diseased or blunted by drugs.^[1]

Why AF causes stroke — Virchow at the appendage

In sinus rhythm the left atrial appendage (LAA) contracts and empties each beat. In AF the atria do not contract; blood stagnates in the LAA, a long, blind-ended, trabeculated pouch. Stasis plus endocardial dysfunction plus hypercoagulability — Virchow's triad applied to AF — makes thrombus that embolises to the brain as a large-territory, often devastating stroke.^[1]

Over 90% of AF-related thrombus forms in the LAA, which is why anticoagulation and, in selected patients, LAA occlusion (e.g. Watchman) are the two stroke-prevention strategies.^[1]

The irregularly irregular pulse — a five-way face-off

An irregularly irregular pulse has a short, high-yield differential, and the ECG splits it in seconds. Name five, then give the one-line discriminator.^[1]

^[1]

The discriminator line: AF is the only one with no P waves at all. MAT has multiple P-wave shapes; ectopics have normal P waves between beats; sinus arrhythmia waxes and wanes with the breath.^[1]

The must-not-miss mimic — pre-excited AF

At the bedside — confirm, destabilise, hunt

The focused assessment has three jobs: confirm the rhythm, judge stability, and hunt for a cause. Do them in that order, because the second one decides drugs-versus-electricity.^[1]

• Confirm. Manual pulse palpation finds an irregularly irregular pulse and a pulse deficit (apex faster than radial; a deficit of more than 10 bpm is significant). But the pulse never makes the diagnosis — an ECG does: 12-lead, or a 30-second strip showing all three hallmarks.^[1]
• Destabilise. The single most important judgement is whether the patient is haemodynamically unstable. Four criteria — hypotension (SBP under 90), acute heart failure or pulmonary oedema, ongoing ischaemic chest pain, reduced GCS — and any one flips you from drugs to the paddles.^[1][2]
• Hunt. Look for thyrotoxicosis (goitre, tremor, eye signs), the rumbling mid-diastolic of mitral stenosis, heart failure (raised JVP, crackles, S3), sepsis, and alcohol stigmata. Every new AF patient gets TFTs.^[1]

Symptoms — and why the elderly hide them

Typical symptoms are driven by loss of the atrial kick (15–30% of stroke volume), the rapid rate, and the irregularity:^[1]

• Palpitations — fast and irregular, abrupt onset and offset in paroxysmal AF.
• Dyspnoea and reduced exercise tolerance — loss of atrial kick and tachycardia.
• Fatigue — the dominant and most under-recognised symptom, especially in the elderly.
• Chest pain — from rate, ischaemia, or the arrhythmia itself.
• Presyncope or syncope — rate-related hypotension, or a sinus pause on termination (brady-tachy syndrome).
• Polyuria — atrial natriuretic peptide release from stretched atria; an under-taught classic clue.^[1]

Bedside signs that reward a careful examiner

• Irregularly irregular pulse — confirm at radial and apex.
• Pulse deficit — apical rate exceeds radial; short filling time makes some beats too weak to reach the wrist.
• Variable S1 intensity — the AV filling interval changes beat to beat, altering mitral closure force.
• Absent "a" waves in the JVP — no coordinated atrial contraction to generate them.
• Signs of a cause: a thyroid goitre, the murmur of mitral disease, crackles and S3 of failure, a septic focus.^[1]

Etymology for viva gold: fibrillation, from the Latin fibrilla, "a small fibre". The word pictures the atria reduced to a quiver of individual muscle fibres — exactly what the ECG and the bedside both show. Sir James Mackenzie nailed the clinical concept from the pulse alone in the early 1900s, decades before the ECG proved him right.^[1]

Investigations — ECG, echo, TFTs, and the two scores

First-line work-up has three aims: confirm the rhythm, find a cause, and grade stroke and bleeding risk.^[1]

^[1]

Ambulatory monitoring is for paroxysmal AF when the resting ECG is normal: a 24–72 h Holter, a patient-activated loop recorder (1–4 weeks), or an implantable cardiac monitor (up to 3 years) — the most sensitive tool for silent AF after cryptogenic stroke.^[1]

Transoesophageal echo (TOE/TEE) does two jobs: it excludes LAA thrombus before cardioversion or ablation (to shorten the 3-week pre-cardioversion window), and it grades the severity of valvular lesions. A thrombus on TOE is an absolute contraindication to cardioversion until it has been treated and resolved.^[1]

CHA2DS2-VASc — "two weigh double, the rest are one"

CHA2DS2-VASc decides who gets anticoagulated, and it is reproduced verbatim. The cluster rule that carries it: two items weigh double — age 75 and prior stroke — everything else is one point.^[1]

• C — Congestive heart failure / LV dysfunction — 1
• H — Hypertension — 1
• A2 — Age 75 or older — 2 (double)
• D — Diabetes — 1
• S2 — Prior stroke, TIA, or systemic thromboembolism — 2 (double)
• V — Vascular disease (prior MI, PAD, aortic plaque) — 1
• A — Age 65–74 — 1
• Sc — Sex category, female — 1^[1]

Maximum is 9 (men) or 10 (women). Anticoagulate at 2 or more in men, 3 or more in women; consider at 1 in men. The trap to name: female sex as the sole point does NOT mandate anticoagulation — a 60-year-old woman with no other risk scores 1 and is generally not anticoagulated.^[1]

^[1]

HAS-BLED — the score that flags, not forbids

HAS-BLED sits beside CHA2DS2-VASc to flag correctable bleeding factors — never to deny anticoagulation. Reproduced verbatim:^[1]

• H — Hypertension (uncontrolled, systolic over 160) — 1
• A — Abnormal renal or liver function — 1 each (max 2)
• S — Prior stroke — 1
• B — Prior major bleeding or predisposition — 1
• L — Labile INR (TTR under 60%, on warfarin) — 1
• E — Elderly (over 65) — 1
• D — Drugs (antiplatelet or NSAID) or excess alcohol — 1 each (max 2)^[1]

Maximum 9. A score of 3 or more signals high bleeding risk and prompts closer monitoring plus attention to the modifiable factors — control the BP, stop the NSAID, cut the alcohol, prefer apixaban.^[1]

Resuscitation — the unstable fork gets the paddles

Enlarge

The first decision in any AF presentation is the only one that is time-critical: stable or unstable? That single judgement bifurcates the whole pathway.^[1]

^[1]

The ABC pathway — "A before B before C"

Modern AF care runs on the ABC pathway (2020 ESC; echoed by the 2023 ACC/AHA/ACCP/HRS update and NICE NG196), and the spine is a sentence you can repeat on any ward round: A before B before C — anticoagulate first, symptom-control second, comorbidity always. All three pillars apply at every AF review, not only at diagnosis.^[1][2]

A — Avoid stroke (anticoagulation)

Anticoagulation is the single best-evidenced intervention in AF and the largest contributor to survival. Anticoagulate at CHA2DS2-VASc 2 or more in men, 3 or more in women; consider at intermediate scores; generally withhold at 0 (men) or 1 (women, sex-only point).^[1][2]

For non-valvular AF, a DOAC is preferred over warfarin — predictable dose response, no routine INR, fewer interactions, equivalent or lower stroke rates with less intracranial bleeding. The four DOACs and their pivotal trials:^[1]

^{[8] [7] [6] [14] [6] [7] [8]}

Reversal, when it bleeds: idarucizumab for dabigatran; andexanet alfa for rivaroxaban, apixaban, and edoxaban. Know the pairing before you reach for it.^[1]

Warfarin (INR 2.0–3.0) stays mandatory for valvular AF (mechanical valve or moderate-to-severe mitral stenosis) and is the fallback where DOACs are unavailable, unaffordable, or contraindicated (advanced renal failure, antiphospholipid syndrome).^[1][2]

Left atrial appendage occlusion (e.g. Watchman) is the option when long-term anticoagulation is contraindicated (a prior life-threatening bleed) and thromboembolic risk is high.^[2]

B — Better symptom control (rate or rhythm)

Rate versus rhythm is symptom-driven, not mortality-driven. AFFIRM settled the question: a routine rhythm-control strategy gave no survival advantage over rate control.^[4]

^{[1] [1] [1]}

Choose rhythm control when: symptoms persist despite rate control; first-episode AF; a treated reversible trigger (e.g. thyrotoxicosis controlled); AF complicating HFrEF (restoring sinus may lift cardiac output); and younger patients, where EAST-AFNET 4 favours an early attempt.^[3]

^{[1] [1] [1]}

Cardioversion and the "3-and-4 rule"

Electrical cardioversion restores sinus in 70–90% when onset is recent. The anticoagulation around it is the rule candidates fumble — call it the 3-and-4 rule: 3 weeks before AND 4 weeks after, regardless of CHA2DS2-VASc.^[1]

1. Conventional (3-and-4): anticoagulate at least 3 weeks before and at least 4 weeks after, because the atria stay mechanically "stunned" for weeks after the rhythm looks normal on the ECG.^[1]
2. TOE-guided: anticoagulate from presentation, TOE to exclude LAA thrombus, cardiovert if clear, then 4 weeks of anticoagulation afterwards.^[1]

Ablation — symptom-driven, not a mortality play

Catheter ablation (pulmonary vein isolation) is the most effective rhythm strategy — sinus in 60–80% of paroxysmal and 40–60% of persistent AF after one or more procedures. But CABANA is the sentence that earns marks: no overall mortality benefit of ablation over drugs on intention-to-treat.^[9][2]

So ablation is symptom- and selection-driven — first choice for symptomatic paroxysmal AF refractory to drugs, and increasingly for AF complicating HFrEF, where subgroup analyses suggest benefit.^[9]

^[9]

C — Comorbidity always

Every review addresses the modifiable drivers that independently predict AF recurrence, progression, and complications. This is pillar C, and it is where long-term outcomes are won or lost.^[1]

• Treat hypertension to target (under 130/80 in most).
• Weight loss — each unit of BMI reduction is associated with AF regression.
• Screen and treat obstructive sleep apnoea with CPAP.
• Reduce alcohol to safe limits or abstain.
• Manage diabetes, ischaemic heart disease, and heart failure to guideline targets.
• Address a sedentary lifestyle — moderate exercise is protective.^[1][2]

Scenarios that change the plan

Paroxysmal AF. A "pill-in-the-pocket" strategy fits infrequent, well-tolerated episodes in selected patients: one oral loading dose of flecainide or propafenone at symptom onset, self-administered only after medical supervision has confirmed the diagnosis and a structurally normal heart. In the pivotal study, 92% of episodes were treated out of hospital, 94% of those converted to sinus, and adverse events were uncommon; emergency visits and admissions fell.^[10]

AF with haemodynamic compromise. Emergency synchronised DC cardioversion — no role for a rate-control drug as the first move in the unstable patient.^[1]

Pre-excited AF (WPW). Broad, irregular tachycardia with delta waves. Never an AV-nodal blocker — use IV procainamide, ibutilide, or amiodarone, or synchronised cardioversion if unstable. Then refer for accessory-pathway ablation.^[2]

Post-cardiac-surgery AF. Occurs in 30–40% after bypass or valve surgery, peaks day 2–3, and is often self-limiting. Rate control (beta-blocker; amiodarone for refractory or pre-existing LV dysfunction) is first-line; anticoagulate by CHA2DS2-VASc, weighing post-op bleeding risk.^[1]

AF in HFrEF. Beta-blocker for rate (avoid diltiazem or verapamil as negative inotropes); digoxin or amiodarone for additional rate. Ablation is favoured in HFrEF — CASTLE-AF and the CABANA HFrEF subgroup suggest benefit in survival and LV function. Dronedarone is contraindicated in unstable HF (PALLAS).^[9][2]

Valvular AF (mitral stenosis or mechanical valve) — warfarin only (INR 2.0–3.0 for mitral stenosis; mechanical-valve target by position and type). DOACs contraindicated.^[1]

The elderly. CHA2DS2-VASc is age-weighted, so almost all elderly AF patients warrant anticoagulation — and HAS-BLED runs high too. Apixaban is often preferred: major bleeding ran lower than warfarin (2.13% vs 3.09% per year, HR 0.69), and the dose falls to 2.5 mg BD when two of three apply — age 80 or more, weight 60 kg or under, creatinine 1.5 mg/dL (133 µmol/L) or more.^[8][13]

Chronic kidney disease. Dose every DOAC by CrCl:^[1]

Pregnancy. Anticoagulate with low-molecular-weight heparin (e.g. enoxaparin), which does not cross the placenta. Warfarin is teratogenic (weeks 6–12) and avoided until the second trimester even in mechanical-valve patients who need it; DOACs are avoided (limited safety data). Rate control with metoprolol (avoid atenolol — fetal growth restriction) or digoxin. AF is uncommon in pregnancy — hunt for a precipitant (thyrotoxicosis, anaemia).^[1]

How AF patients come to harm — the preventable list

AF rarely kills by the rhythm itself; it kills through five complications, and most are preventable. Name all five on a viva.^[1]

^[1]

The seven ways you personally cause harm

Prognosis and disposition

Prognosis tracks the same three pillars as management — stroke prevention, symptom control, comorbidity. Untreated AF roughly doubles all-cause mortality, mostly via stroke and heart failure; appropriate anticoagulation, rate or rhythm control, and risk-factor work largely abolish the excess.^[1]

The three prognosis trials to hold:^[1]

^{[3] [4] [5]}

Disposition. Stable, rate-controlled AF is managed as an outpatient — oral rate-control, anticoagulation if indicated, primary-care or cardiology follow-up. Admit for haemodynamic instability, rapid AF needing IV rate or rhythm control, a new embolic stroke, a suspected serious cause (acute MI, decompensated HF, thyrotoxic storm, sepsis), or complex therapy (e.g. IV amiodarone with monitoring).^[1]

At every follow-up: confirm anticoagulation adherence (DOAC, or INR if warfarin), re-check CHA2DS2-VASc and HAS-BLED, assess symptom control and recheck heart rate, review renal and hepatic function for dose adjustments, reinforce modifiable targets (weight, BP, alcohol, sleep apnoea), and arrange ECG monitoring for paroxysmal recurrence.^[1]

The two governing guidelines

Two deeply evidence-based guidelines govern AF care, and they agree on almost everything.^[1]

• 2020 ESC Guidelines (Hindricks et al., 2021) — introduced the ABC pathway, the DOAC-preference framework for non-valvular AF, early rhythm control (echoing EAST-AFNET 4), and aggressive risk-factor modification.^[1]
• 2023 ACC/AHA/ACCP/HRS Guideline (Joglar et al., 2024) — broadly concordant; explicitly endorses DOAC preference, LAA occlusion for selected patients, ablation in HFrEF, and risk-factor modification.^[2]

NICE NG196 (UK) is aligned: DOAC first for non-valvular AF, ABC pathway, lenient rate control, ablation for drug-refractory symptomatic paroxysmal AF.^[1]

The live controversy is the upstream shift — from routine rate control toward early rhythm control (EAST-AFNET 4) and aggressive risk-factor modification, before remodelling is established.^[3]

Exam pearls — the page in one screen

• ECG: irregularly irregular RR, absent P waves, f-waves at 350 to 600 per minute.
• Classification: paroxysmal (self-terminates within 7 days, usually 48 h); persistent (longer than 7 days); long-standing persistent (longer than 12 months); permanent (accepted).
• CHA2DS2-VASc: two weigh double (age 75+, prior stroke); anticoagulate at 2 or more in men, 3 or more in women; female sex alone is not enough.^[11][15]
• HAS-BLED 3 or more = high bleeding risk; flags correctable factors; does NOT deny anticoagulation.
• Valvular AF (mechanical valve or moderate-severe mitral stenosis) = warfarin only, INR 2.0–3.0; DOAC contraindicated.
• Apixaban 5 mg BD; reduce to 2.5 mg BD if two or more of age 80+, weight 60 kg or under, creatinine 1.5 mg/dL (133 µmol/L) or more.
• Rivaroxaban 20 mg OD; 15 mg OD at CrCl 30 to 49.^[12]
• Dabigatran 110 or 150 mg BID; the 150 mg dose cut stroke or embolism further than warfarin (RR 0.66).^[6]
• Edoxaban once-daily, two regimens, both noninferior to warfarin with less bleeding on the higher one.^[14]
• Reversal: idarucizumab (dabigatran), andexanet alfa (rivaroxaban/apixaban/edoxaban).
• Lenient rate target: resting ventricular rate under 110 bpm (RACE II).
• Rate drugs: bisoprolol 5 mg OD (2.5–10); diltiazem 180–240 mg OD MR; digoxin 0.125–0.25 mg OD.
• Rhythm: flecainide 50–100 mg BD or 200 mg pill-in-the-pocket (avoid IHD/structural/HFrEF; co-prescribe an AV-nodal blocker); amiodarone 200 mg TDS then BD then OD (safest in HFrEF); sotalol 80–160 mg BD (QT); dronedarone 400 mg BD (avoid HFrEF or permanent — PALLAS).
• Cardioversion: synchronised biphasic 120–200 J; the 3-and-4 rule — 3 weeks before AND 4 weeks after (or TOE-guided), regardless of CHA2DS2-VASc.
• Unstable AF (SBP under 90, acute HF, ongoing ischaemic chest pain, reduced GCS) = synchronised DC cardioversion, not drugs.
• Pre-excited AF: broad irregular tachycardia with delta waves; NEVER an AV-nodal blocker — procainamide, ibutilide, or amiodarone, or cardiovert.
• Trials: AFFIRM (no survival advantage for routine rhythm); EAST-AFNET 4 (early rhythm improves composite CV outcome); RACE II (lenient rate control non-inferior); RE-LY, ROCKET AF, ARISTOTLE (the DOACs); CABANA (ablation no overall mortality benefit; symptom-driven, benefit in HFrEF).^[1]

Ward-round test

1. A 76-year-old woman, hypertension and diabetes, new AF. CHA2DS2-VASc? Anticoagulation?ShowHide

Score it: age 75+ = 2, HTN = 1, DM = 1, female sex = 1, total 5. Anticoagulate — a DOAC (apixaban 5 mg BD, dose-reduced to 2.5 mg BD only if she meets two of age 80+, weight 60 kg or under, creatinine 1.5 mg/dL or more). Run HAS-BLED to flag correctable factors, but a high score does not deny anticoagulation.^[15][8][13]

2. Broad irregular tachycardia, delta waves, SBP 84. First drug?ShowHide

This is pre-excited AF (WPW) — and it is unstable. Do not give adenosine, a calcium-channel blocker, a beta-blocker, or digoxin (each can accelerate the accessory pathway to VF). Synchronised DC cardioversion now. If a drug is genuinely needed and the patient is stable, IV procainamide, ibutilide, or amiodarone.^[2]

3. Symptom-free permanent AF, resting ventricular rate 104. Change the rate drug?ShowHide

No. RACE II made lenient rate control (resting rate under 110 bpm) the default in stable permanent AF — he is at target. Tighten only if symptomatic or if HFrEF with tachycardiomyopathy is a concern.^[5]

4. Elective cardioversion planned six weeks out. Anticoagulation?ShowHide

The 3-and-4 rule: at least 3 weeks of anticoagulation before and at least 4 weeks after, regardless of CHA2DS2-VASc — the atria are mechanically stunned even once the ECG shows sinus. Alternatively, TOE-guided: anticoagulate from now, TOE to exclude LAA thrombus, cardiovert if clear, then 4 weeks after.^[1]

References15ShowHide

1. [1]Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Eur Heart J, 2021.PMID 32860505
2. [2]Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Circulation, 2024.PMID 38033089
3. [3]Kirchhof P, Camm AJ, Goette A, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation N Engl J Med, 2020.PMID 32865375
4. [4]Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation N Engl J Med, 2002.PMID 12466506
5. [5]Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation N Engl J Med, 2010.PMID 20231232
6. [6]Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med, 2009.PMID 19717844
7. [7]Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med, 2011.PMID 21830957
8. [8]Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med, 2011.PMID 21870978
9. [9]Packer DL, Mark DB, Robb RA, et al. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial JAMA, 2019.PMID 30874766
10. [10]Alboni P, Botto GL, Baldi N, et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach N Engl J Med, 2004.PMID 15575054
11. [11]Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: a euro heart survey on prospective cohort study Chest, 2010.PMID 19762550
12. [12]Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate-to-severe renal impairment Eur Heart J, 2011.PMID 21873708
13. [13]Zeitouni M, Giczewska A, Lopes RD, et al. Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial J Am Coll Cardiol, 2020.PMID 32164888
14. [14]Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med, 2013.PMID 24251359
15. [15]Abouzid MR, Kamel I, Saleh A, et al. Assessing Stroke and Mortality Risk in Heart Failure: The CHA2DS2-VASc Score's Prognostic Value in Patients With and Without Atrial Fibrillation: A Meta-Analysis Cardiol Rev, 2024.PMID 39145638